Journal of Medicinal Chemistry · 2017 · 58 citations · 43 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryLead OptimizationLigand BindingLigand-based DesignMacrocyclic Drug DesignNatural Product-based Drug DesignPotency OptimizationStereochemical OptimizationBinding Mode OptimizationChemical Synthesis Of AnaloguesCompound Potency OptimizationMacrocycle Library SynthesisMacrocyclic InhibitorsSimplificationStructural Simplificationπ Stacking
Cyclophilin inhibition has been a target for the treatment of hepatitis C and other diseases, but the generation of potent, drug-like molecules through chemical synthesis has been challenging. In this study, a set of macrocyclic cyclophilin inhibitors was synthesized based on the core structure of the natural product sanglifehrin A. Initial compound optimization identified the valine-m-tyrosine-piperazic acid tripeptide (Val-m-Tyr-Pip) in the sanglifehrin core, stereocenters at C14 and C15, and the hydroxyl group of the m-tyrosine (m-Tyr) residue as key contributors to compound potency. Replacing the C18-C21 diene unit of sanglifehrin with a styryl group led to potent compounds that displayed a novel binding mode in which the styrene moiety engaged in a π-stacking interaction with Arg55 of cyclophilin A (Cyp A), and the m-Tyr residue was displaced into solvent. This observation allowed further simplifications of the scaffold to generate new lead compounds in the search for orally bioavailable cyclophilin inhibitors.
43
<i>Phaser</i>crystallographic software
Airlie J. McCoy, Ralf W. Grosse‐Kunstleve, Paul D. Adams et al. · Journal of Applied Crystallography · 2007 · 20.9K citations · Full text
Cyclophilin: A Specific Cytosolic Binding Protein for Cyclosporin A
Robert E. Handschumacher, Matthew W. Harding, Jeffrey S. Rice et al. · Science · 1984 · 1.7K citations
Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins
Günter Fischer, Brigitte Wittmann‐Liebold, Kurt Lang et al. · Nature · 1989 · 1.4K citations